Endocrine Abstracts

Background: Polycystic ovary syndrome (PCOS) is a common endocrine condition in women at reproductive age, in whom, glucose metabolism disturbances are commonly observed. In addition, overweight and obesity, especially visceral obesity, are more prevalent in PCOS women, which enhances the resistance to insulin action, and as consequence, the onset of impaired glucose tolerance (IGT) and/or type 2 diabetes mellitus (T2DM). Clinical guidelines recommend oral glucose tolerance te...

IntroductionEctopic Cushing’s syndrome (ECS) is a rare entity caused by ACTH secretion by a non-pituitary tumor. The management of these patients is challenging due to its low frequency and limited experienced. The objective of this study was to describe the patients with ECS treated in the Division of Endocrinology at the Ramón y Cajal University Hospital (Madrid, Spain) in the last six years.Methods<p class="abstext...

Metabolic-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCC), but the molecular mechanisms associated with the pathological progression from MAFLD to HCC are still to be fully elucidated. The genomic and transcriptomic profile of HCC samples have been widely described; however, the proteomic landscape of MAFLD-derived HCC samples is mostly unknown. Here, we sought to perform the first quantitative proteomic analysis of HCC samples from ...

Metabolic associated fatty liver disease (MAFLD) is rapidly becoming a major aetiology for the development of hepatocellular carcinoma (HCC, the most common liver cancer) in the context of chronic liver disease. Current therapeutical options for MAFLD (dietetic/lifestyle intervention and/or pharmacological approaches) are still insufficient and the cellular and molecular mechanisms underlying this disease are yet to be fully understood. Our group previously reported that the n...

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

Acromegaly is caused by excessive GH secretion from pituitary adenomas. Transphenoidal surgery is the first-choice treatment, but new drug therapies (e.g. somatostatin analogues, SSA) offer promising avenues for medical treatment. Complementary diagnostic tools may assist this strategy, helping to refine drug choice. Here, we investigate the associations between radiological features and molecular phenotype of pituitary tumours from acromegalic patients. This observational stu...

Hormonal signalling plays a key role in the progression of metabolic (dysfunction)-associated fatty liver disease (MAFLD) to hepatocellular carcinoma (HCC). However, the role of somatostatin (SST), cortistatin (CORT), neuronostatin (NST) and ghrelin systems in MAFLD-HCC progression has not yet been elucidated. We characterized the role of SST/CORT/NST and ghrelin systems in chronic liver disease and evaluated their clinical potential. The expression of the components of the SS...

Introduction: The incidence of papillary thyroid microcarcinomas (MPT, max diameter≤10 mm) has increased in recent years. Most have a very good prognosis but some have growth during follow-up, lymph node and / or distant metastases.Material and methods: We performed a single-center, retrospective cohort study, n=114 patients (86% women, average age 48.3 years), diagnosed with MPT between 1998 and 2012. Risk stratification system (ATA 2015): 10 high...

Prostate cancer (PCa) is one of the leading causes of cancer deaths among men population worldwide. This tumour pathology is commonly diagnosed through the determination of serum PSA levels. However, the diagnostic capability of PSA dramatically drops when considering patients with PSA levels lower than 10 ng/ml, the so-called “grey-zone”1. Therefore, additional non-invasive diagnostic biomarkers are urgently needed to substitute/complement PSA. In this se...

Endocrine-metabolic alterations such as obesity and metabolic syndrome are closely linked to the development of chronic liver diseases, from metabolic-associated fatty liver (MAFLD) to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). An emerging hallmark of endocrine-metabolic and hepatic diseases is the appearance or altered expression of pathological splicing variants (SVs). In fact, the components of the cellular machinery involved in the splicing pr...